Is there a reason for concern or is it just hype? – A
systematic literature review of the clinical
consequences of switching from originator biologics
to biosimilars
Inotai, A., Prins, C., Csanádi, M., Vitezić, D., Codreanu, C. i Kaló, Z. (2017). Is there a reason for concern or is it just hype? – A
systematic literature review of the clinical
consequences of switching from originator biologics
to biosimilars. Expert opinion on biological therapy, 17. (8), 915-926. doi: 10.1080/14712598.2017.1341486
Inotai, András, et al. "Is there a reason for concern or is it just hype? – A
systematic literature review of the clinical
consequences of switching from originator biologics
to biosimilars." Expert opinion on biological therapy, vol. 17, br. 8, 2017, str. 915-926. https://doi.org/10.1080/14712598.2017.1341486
Inotai, András, Christiaan Prins, Marcell Csanádi, Dinko Vitezić, Catalin Codreanu i Zoltán Kaló. "Is there a reason for concern or is it just hype? – A
systematic literature review of the clinical
consequences of switching from originator biologics
to biosimilars." Expert opinion on biological therapy 17, br. 8 (2017): 915-926. https://doi.org/10.1080/14712598.2017.1341486
Inotai, A., et al. (2017) 'Is there a reason for concern or is it just hype? – A
systematic literature review of the clinical
consequences of switching from originator biologics
to biosimilars', Expert opinion on biological therapy, 17(8), str. 915-926. doi: 10.1080/14712598.2017.1341486
Inotai A, Prins C, Csanádi M, Vitezić D, Codreanu C, Kaló Z. Is there a reason for concern or is it just hype? – A
systematic literature review of the clinical
consequences of switching from originator biologics
to biosimilars. Expert opinion on biological therapy [Internet]. 2017. [pristupljeno 01.10.2024.];17(8):915-926. doi: 10.1080/14712598.2017.1341486
A. Inotai, C. Prins, M. Csanádi, D. Vitezić, C. Codreanu i Z. Kaló, "Is there a reason for concern or is it just hype? – A
systematic literature review of the clinical
consequences of switching from originator biologics
to biosimilars", Expert opinion on biological therapy, vol. 17, br. 8, str. 915-926, 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:992083. [Citirano: 01.10.2024.]